Results 1-5 of 5 for drugs segment:8868285

Select Committee on Health: Health (Miscellaneous Provisions) Bill 2024: Committee Stage (21 Mar 2024)

...of buffering, but we will try to encourage a recognition of our interdependence within the global arena and the importance of the flow of medicines. We have arrangements nationally to monitor drugs going into a shortage of supply and this legislation will absolutely strengthen the information base we will have for that. Mr. Warren might wish to come in on the shortages framework.

Select Committee on Health: Health (Miscellaneous Provisions) Bill 2024: Committee Stage (21 Mar 2024)

David Cullinane: ...a wider lens. The industry will look at it through its own lens but we have to look at it through a wider lens. I would imagine the logic of the directive is to have greater access to generic drugs, which we also need, but there is a need for caution on the part of the State. The pharmaceutical sector, as we know, is very important to the Irish economy. It creates a lot of jobs and a...

Select Committee on Health: Health (Miscellaneous Provisions) Bill 2024: Committee Stage (21 Mar 2024)

David Cullinane: ...states the US will be watching this with regard to anything that makes it more difficult for a company to protect its intellectual property, particularly when there is large investment in high-tech drugs, and we all know how important that is for patients and the industry. I get that there is a balance to be struck. I get all of these points. I fully understand the issues relating to...

Select Committee on Health: Health (Miscellaneous Provisions) Bill 2024: Committee Stage (21 Mar 2024)

...throughout Europe has a clear understanding of the parameters. As Deputy Cullinane knows, we have a very strong genetic pharmaceutical industry that has an interest quite contrary to the new drug developers. The genetic pharmaceutical industry has an interest in shortening the period and then the production at scale of drugs that prove effective in genetic format.

Select Committee on Health: Health (Miscellaneous Provisions) Bill 2024: Committee Stage (21 Mar 2024)

...commitment to this market access would grant an extra two years' exclusivity. A commitment to clinical trials beyond launch, of which there are not half enough in terms of testing the efficacy of drugs in the real world, would buy six months' exclusivity in the proposals. There would also be some incentivisation of drugs that might not be greatly profitable but are vital, such as...